Cocrystal Pharma, Inc. (COCP) –
-
Form 10-K/A Cocrystal Pharma, Inc. For: Dec 31
-
Form 10-K Cocrystal Pharma, Inc. For: Dec 31
-
Form 8-K Cocrystal Pharma, Inc. For: Mar 28
-
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
-
Form 8-K Cocrystal Pharma, Inc. For: Mar 19
-
Cocrystal Pharma (COCP) Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
-
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
-
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
-
Form 8-K Cocrystal Pharma, Inc. For: Feb 28
-
Form 8-K Cocrystal Pharma, Inc. For: Jan 08
-
Form 8-K Cocrystal Pharma, Inc. For: Jan 04
-
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
-
Form SC 13G/A Cocrystal Pharma, Inc. Filed by: SABBY MANAGEMENT, LLC
-
Form 8-K Cocrystal Pharma, Inc. For: Dec 15
-
Form 8-K Cocrystal Pharma, Inc. For: Dec 06
-
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
-
Form 8-K Cocrystal Pharma, Inc. For: Dec 04
-
Form 8-K Cocrystal Pharma, Inc. For: Nov 28
-
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
-
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
-
Cocrystal Pharma, Inc. (COCP) Tops Q3 EPS by 12c
-
Form 8-K Cocrystal Pharma, Inc. For: Nov 13
-
Form 10-Q Cocrystal Pharma, Inc. For: Sep 30
-
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
-
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
-
Form 8-K Cocrystal Pharma, Inc. For: Oct 31
-
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
-
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
-
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
-
Form 8-K Cocrystal Pharma, Inc. For: Aug 14
-
Form 10-Q Cocrystal Pharma, Inc. For: Jun 30
-
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
-
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
-
Form 4 Cocrystal Pharma, Inc. For: Jul 18 Filed by: Martin James Joseph
-
Form 4 Cocrystal Pharma, Inc. For: Jul 18 Filed by: PFENNIGER RICHARD C JR
-
Form 4 Cocrystal Pharma, Inc. For: Jul 18 Filed by: FROST PHILLIP MD ET AL
-
Form 4 Cocrystal Pharma, Inc. For: Jul 18 Filed by: Japour Anthony J
-
Form 4 Cocrystal Pharma, Inc. For: Jul 18 Filed by: Kornberg Roger D.
-
Form 4 Cocrystal Pharma, Inc. For: Jul 18 Filed by: Lee Sam
-
Form 4 Cocrystal Pharma, Inc. For: Jul 18 Filed by: Rubin Steven D
-
Form 4 Cocrystal Pharma, Inc. For: Jul 18 Filed by: Hassan Fred
-
Form 8-K Cocrystal Pharma, Inc. For: Jun 15
-
Form 424B5 Cocrystal Pharma, Inc.
-
Form 8-K Cocrystal Pharma, Inc. For: Jun 08
-
Cocrystal Pharma (COCP) Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988
-
Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988
-
Form EFFECT Cocrystal Pharma, Inc.
-
Cocrystal Pharma, Inc. (COCP) Files $150M Mixed Shelf
-
Form S-3/A Cocrystal Pharma, Inc.
-
Form 8-K Cocrystal Pharma, Inc. For: May 15
Back to COCP Stock Lookup
